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Abstract: One step of the life cycle common among all rotaviruses (RV) studied so far is the formation
of viroplasms, membrane-less cytosolic inclusions providing a microenvironment for early morphogenesis
and RNA replication. Viroplasm-like structures (VLS) are simplified viroplasm models consisting of com-
plexes of non-structural protein 5 (NSP5) with either the RV core-shell VP2 or NSP2. We identified and
characterized the domains required for NSP5-VP2 interaction and VLS formation. VP2 mutations L124A,
V865A, or I878A impaired both NSP5 hyperphosphorylation and NSP5/VP2 VLS formation. Moreover,
NSP5-VP2 interaction does not depend on NSP5 hyperphosphorylation. The NSP5 tail region is re-
quired for VP2 interaction. Notably, VP2 L124A expression acts as dominant-negative by disrupting the
formation of either VLSs or viroplasms and blocking RNA synthesis. <jats:italic>In silico</jats:italic>
analyses revealed that VP2 L124, V865, and I878 are conserved among RV A to H species. The detailed
knowledge of the protein interaction interface required for viroplasm formation may facilitate the design
of broad-spectrum antivirals to block RV replication. <jats:bold>Importance</jats:bold> Alternative
treatments to combat rotavirus infection are a requirement for susceptible communities where vaccines
cannot be applied. This demand is urgent for newborn infants, immunocompromised patients but also
for adults traveling to high-risk regions and even for livestock industry. Aside from structural and physi-
ological divergences among RV species studied until now, all replicate within cytosolic inclusions termed
viroplasms. These inclusions are composed of viral and cellular proteins and viral RNA. Viroplasm-like
structures (VLS), composed of RV proteins NSP5 with either NSP2 or VP2, are models for investigating
viroplasms. In this study, we identified a conserved amino acid in the VP2 protein, L124, necessary for its
interaction with NSP5 and the formation of both VLSs and viroplasms. As RV vaccines cover a narrow
range of viral strains, the identification of VP2 L124 residue lays the foundations for the design of drugs
that specifically block NSP5-VP2 interaction as a broad-spectrum RV antiviral.
DOI: https://doi.org/10.1128/jvi.01965-19





Buttafuoco, Antonino; Michaelsen, Kevin; Tobler, Kurt; Ackermann, Mathias; Fraefel, Cornel; Eichwald,









, Kevin Michaelsen 
a
, Kurt Tobler 
a
, Mathias Ackermann 
a
, Cornel 3 
Fraefel 
a






Institute of Virology, University of Zurich, 8057 Zurich, Switzerland. 6 
 7 
Running Head: NSP5-VP2 interaction region 8 
 9 
 10 
# Address correspondence to Catherine Eichwald, ceichwald@vetvir.uzh.ch 11 
Word counts for abstract and text are 167 and 7’782, respectively 12 
 13 
  14 
JVI Accepted Manuscript Posted Online 8 January 2020
J. Virol. doi:10.1128/JVI.01965-19



































































Abstract. One step of the life cycle common among all rotaviruses (RV) studied so far 15 
is the formation of viroplasms, membrane-less cytosolic inclusions providing a 16 
microenvironment for early morphogenesis and RNA replication. Viroplasm-like 17 
structures (VLS) are simplified viroplasm models consisting of complexes of non-18 
structural protein 5 (NSP5) with either the RV core-shell VP2 or NSP2. We identified 19 
and characterized the domains required for NSP5-VP2 interaction and VLS formation. 20 
VP2 mutations L124A, V865A, or I878A impaired both NSP5 hyperphosphorylation and 21 
NSP5/VP2 VLS formation. Moreover, NSP5-VP2 interaction does not depend on NSP5 22 
hyperphosphorylation. The NSP5 tail region is required for VP2 interaction. Notably, 23 
VP2 L124A expression acts as dominant-negative by disrupting the formation of either 24 
VLSs or viroplasms and blocking RNA synthesis. In silico analyses revealed that VP2 25 
L124, V865, and I878 are conserved among RV A to H species. The detailed knowledge 26 
of the protein interaction interface required for viroplasm formation may facilitate the 27 
design of broad-spectrum antivirals to block RV replication. 28 
 29 
Keywords: NSP5 /protein-interface/ VP2 / rotavirus / viroplasm 30 
Importance. Alternative treatments to combat rotavirus infection are a requirement for 31 
susceptible communities where vaccines cannot be applied. This demand is urgent for 32 
newborn infants, immunocompromised patients but also for adults traveling to high-risk 33 
regions and even for livestock industry. Aside from structural and physiological 34 



































































termed viroplasms. These inclusions are composed of viral and cellular proteins and viral 36 
RNA. Viroplasm-like structures (VLS), composed of RV proteins NSP5 with either 37 
NSP2 or VP2, are models for investigating viroplasms. In this study, we identified a 38 
conserved amino acid in the VP2 protein, L124, necessary for its interaction with NSP5 39 
and the formation of both VLSs and viroplasms. As RV vaccines cover a narrow range of 40 
viral strains, the identification of VP2 L124 residue lays the foundations for the design of 41 
drugs that specifically block NSP5-VP2 interaction as a broad-spectrum RV antiviral. 42 




































































Rotaviruses (RVs) are dsRNA viruses of the Reoviridae family and are responsible 45 
for severe gastroenteritis in infants and young children, killing approx. 128,000 children 46 
per year, mainly in developing countries (1). RV virions are organized in three concentric 47 
layers surrounding the viral genome. The spike protein VP4 and the glycoprotein VP7 48 
form the outermost layer, while VP6 makes up the intermediate layer. The innermost 49 
layer, the core-shell, is composed of 120 copies of VP2, organized in twelve asymmetric 50 
decamers (2). Each core-shell encapsidates the eleven segments of the viral genome as 51 
well as the replication complexes composed of the RNA-depended RNA polymerase 52 
(RdRp) VP1 and the guanylyl-methyltransferase VP3. There is evidence that one 53 
replication complex locates beneath each 5-fold axis of the twelve VP2 decamers (2, 3). 54 
During virus entry, the external layer is lost, and a transcriptionally active double-layered 55 
particle is released into the cytosol (4). The newly released transcripts enable the 56 
synthesis of viral proteins necessary for viral replication. Among those proteins, the 57 
NTPase/RTPase NSP2 and the phosphoprotein NSP5, together with the structural 58 
proteins VP1, VP2, VP3, and VP6, and the non-structural NSP4, constitute the RV viral 59 
factories termed viroplasms (5, 6). The viroplasms correspond to membrane-less 60 
cytosolic electron-dense inclusions where viral genome transcription and replication, as 61 
well as the packaging of the newly synthesized pre-genomic RNA segments into the viral 62 
cores, take place. Interestingly, co-expression of the main viroplasm protein NSP5 with 63 
either NSP2 or VP2 leads to the formation of cytosolic inclusions named viroplasm-like 64 
structures (VLS) that are morphologically similar to viroplasms but unable to yield viral 65 



































































since they share physiological traits with viroplasms, including coalescence and 67 
perinuclear condensation (10, 13-15). NSP5 is hyperphosphorylated (16, 17) and O-68 
GlcNAc-glycosylated (18). While the role of NSP5 phosphorylation in RV replication 69 
remains obscure, it has been demonstrated that NSP2 or VP2 are required to enhance the 70 
hyper-phosphorylation state (19, 20). Moreover, NSP5 is required for viroplasm 71 
formation and virus replication, as shown by knockdown experiments using siRNAs (21, 72 
22). NSP5 has a multifunctional role in the RV lifecycle, interacting with NSP6 (12), 73 
NSP2 (9), VP1 (23), VP2 (24) and in an unspecific manner with dsRNA (25), which also 74 
is consistent with its predicted partially unfolded nature (26-28). NSP5 was recently 75 
described as covalently sumoylated (29), suggesting that this modification might be a pre-76 
requirement for the interaction with viral or host components. Taken these studies 77 
together, NSP5 can be considered an essential component for RV replication. Likewise, 78 
the core-shell protein VP2, besides its structural function protecting the viral genome, is 79 
also able to activate and regulate the RdRp VP1 protein (30), permitting genome 80 
replication. In TLPs and DLPs, VP2 spontaneously oligomerizes by forming an 81 
asymmetric decameric structure with VP2 isoforms A and B that converges in the 5-fold 82 
axis, which cannot dissociate (2, 28, 31-33). Each subunit of the decamer is composed of 83 
a primary domain of VP2 (residues ~ 100 to 880), forming a thin coma shaped plate, 84 
which in turn also divides into three subdomains: apical, central and dimer forming. The 85 
N-terminal domain (NTD) (residues ~1 to 100 for type A and ~1 to 80 for type B) is 86 
unfolded and localizes in the decamer beneath the 5-fold axis. VP1, VP3, VP6, and NSP2 87 
(2, 34-36), as well as unspecific ssRNA (37), have been mapped to bind to VP2, most of 88 



































































with the VP2 scaffold region, for example, VP1, which contacts the VP2 region 341-374 90 
(38-40). These interactions are all directly related to the core-shell structure and genome 91 
replication and transcription. VP2 is also a main component of the viroplasms, as denoted 92 
by immunofluorescence of RV infected cells and its ability to form VLS when co-93 
expressed with NSP5 (7, 10, 41). The VLSs induced by VP2 (hereafter, VLS) are 94 
dynamic and able to shift to the perinuclear region by a mechanism that is still under 95 
investigation (10). Further evidence indicates that VP2 triggers NSP5 96 
hyperphosphorylation (7). Recently it has been suggested that VP2 may have additional 97 
roles at early times post-infection because of its interaction with NSP2, preventing its 98 
spontaneous oligomerization and sumoylation, which increases the ability of VP2 to 99 
interact with other proteins (10, 29). Therefore, we hypothesized that the interaction of 100 
these two proteins to form VLS is an essential step for RV replication.  101 
In this study, we show that specific point mutations in VP2 abrogate VLS formation 102 
by disrupting NSP5 binding and phosphorylation. Additionally, we demonstrate that 103 
NSP5 requires its 18 C-terminal amino acids to interact with VP2 directly. Importantly, 104 
VP2 harboring the point mutation L124A disrupts VLS induced by the expression of 105 
NSP5-VP2 and NSP5-NSP2. Similarly, in RV-infected cells, VP2 L124A expression 106 
results in a reduced number of infected cells, and viroplasms with aberrant structures and 107 
defective in viral RNA synthesis. Altogether, these data provide a mechanistic 108 






































































VP2 amino acid regions 103-135 and 840-880 are necessary for VLS formation with 113 
NSP5. To elucidate the nature of the association between NSP5 and VP2, we assessed the 114 
capacity of these two proteins to form viroplasm-like structures when co-expressed in the 115 
absence of other rotavirus proteins (7). To this end, and as denoted in Fig 1A, we 116 
constructed a series of VP2 mutants by deleting N-terminal and C-terminal regions as 117 
well as constructs expressing single regions of the protein based on the published tertiary 118 
VP2 structure (42). For the detection of the VP2 deletion mutants, a human influenza 119 
virus hemagglutinin (HA) tag was added at the N-terminus. All HA-VP2 deletion mutants 120 
were verified by immunoblotting for correct expression and size (data not shown). Next, 121 
we performed immunofluorescence analysis of co-transfected cells to assess VLS 122 
formation, which was considered positive only when co-localization of both HA-VP2 and 123 
NSP5 was observed in cytosolic inclusions. The results, summarized in Fig 1, show that 124 
full-length HA-VP2 (fl) was homogeneously distributed in the cytosol of transfected cells 125 
(Fig 1B, top row, -NSP5). However, when HA-VP2fl was co-expressed with NSP5 (Fig 126 
1B, top row, +NSP5), it formed cytosolic inclusions that co-localized with NSP5, 127 
corresponding to VLSs. In the presence of NSP5, HA-VP2∆N103 was able to form 128 
VLSs, while HA-VP2∆N135 was not (Fig 1B). The shortest HA-VP2 C-terminal deletion 129 
mutant tested (Fig 1B), HA-VP2 ∆C840, was also unable to form VLSs when co-130 
expressed with NSP5, suggesting that the amino acid region 840 to 880 is necessary for 131 
VLS formation with NSP5 as well. Of note, none of the constructs that tested positive for 132 



































































shown), suggesting that the observed structures correspond to genuine VLS. This data 134 
indicates that the amino acid regions from 103-135 and 840-880 of VP2 are necessary for 135 
VLSs formation between VP2 and NSP5. As expected, none of the HA-VP2 single 136 
regions formed VLSs when co-expressed with NSP5. A summary of the results of all 137 
HA-VP2 deletion mutants tested for VLS formation is shown in the right column of Fig 138 
1A.  139 
VP2 amino acids L124, V865, and I878 are required for VLS formation. We next 140 
determined the residues in region 103-135 of VP2 (RV simian strain SA11) that are 141 
relevant for VLS formation. For this, we first performed primary sequence alignment of 142 
all VP2 proteins from species A to H (Fig 2A). This analysis revealed that four amino 143 
acid residues are highly conserved among all the aligned VP2 proteins, specifically I106, 144 
D112, L124, and I127. To analyze their role in VLS formation, we mutated each of these 145 
residues to alanine in HA-VP2∆N103, which is the minimal HA-VP2 deletion mutant 146 
able to form VLS when co-expressed with NSP5. The point mutations I106A, D112A, 147 
and I127A (data not shown), as well as the parent construct (HA-VP2∆N103), supported 148 
the formation of VLS together with NSP5 while HA-VP2∆N103 (L124A) did not. VP2 149 
carrying this point mutation (L124A) was also not able to form VLS with NSP5 when 150 
introduced into a full-length untagged VP2 (Fig 2C) while wild type (wt) VP2 and VP2 151 
D112A did (D112A was chosen as a positive control for NSP5-HA-VP2∆N103 VLS 152 
formation (data not shown)).  153 
 Similarly, as for the VP2 region 103-135, we aligned the amino acid region 840 to 154 
880 of VP2-SA11 using all the NCBI deposited sequences for VP2. This alignment 155 



































































F873, and I878, in RV species A-H (Fig 2B). Interestingly, F850 was highly conserved 157 
among RVA, RVC, RVF, and RVD species but absent in RVB, RVG, and RVH species. 158 
We mutated each of these residues to alanine in wt VP2 and tested for VLS formation in 159 
co-expression with NSP5. As shown in Fig 2C, wt VP2, and VP2 harboring point 160 
mutations M843A, F850A, L856A, V860A, and F873A were able to form VLS. In 161 
contrast, VP2 harboring a point mutation in residues V865 and I878 was unable to form 162 
VLS. In contrast to wt VP2, the mutants VP2 V865A and I878A do not diffuse 163 
homogeneously in the cytosol. However, they did not form aggresomes (data not shown), 164 
either, suggesting the spontaneous generation of genuine or aberrant core-like structures. 165 
All the other point mutations maintained their ability to form VLS. Importantly, as 166 
observed in Fig 3A, cognate NSP5(SA11)-VP2(SA11) pairs, as well as unrelated 167 
NSP5(OSU)-VP2(SA11), can form VLSs. Meanwhile, VP2L124A impairs VLS either 168 
with NSP5 (SA11) or NSP5(OSU). Collectively, our data suggest that L124, V865, and 169 
I878 of VP2-SA11 are necessary for VLS formation in the presence of NSP5. 170 
VP2 residues L124, V865, and I878 are required for triggering NSP5 171 
hyperphosphorylation. NSP5 is a phosphoprotein that during RV-infection shows a 172 
mobility shift on SDS-PAGE corresponding to a hyperphosphorylated pattern (16, 17). 173 
However, when NSP5 is expressed in the absence of other viral proteins, it is detected 174 
only as a single band (19). Interestingly, it has been described that the co-expression of 175 
NSP5 with NSP2 (19) and VP2 (7) triggers the NSP5 hyperphosphorylation pattern. In 176 
order to determine which VP2 regions are involved in triggering the NSP5 177 
hyperphosphorylation, we analyzed cell extracts co-expressing NSP5 in the presence of 178 



































































shown in Fig 4, wt VP2 and VP2∆N81 (Fig 4A, lanes 2-3, and Fig 4B, lane 2) triggered 180 
NSP5 hyperphosphorylation, while all other VP2 deletion mutants tested did not (Fig 4A 181 
lanes 4-7 and Fig 4B lanes 3-7), as the NSP5 pattern was comparable to that when NSP5 182 
is expressed alone (Figs 4A and 4B, lane 1). Similarly, VP2 proteins harboring L124A, 183 
V865A, and I878A point mutations (Fig 4C, lanes 3-5, and Fig 3B, lanes 3 and 6) failed 184 
to induce NSP5 hyperphosphorylation as well (Fig 4C, lane 2 and Fig 3B lanes 2 and 4). 185 
As previously demonstrated (19), the treatment of cellular extracts with lambda-186 
phosphatase confirmed that the NSP5 PAGE mobility-shift corresponds to 187 
phosphorylation (Fig 4D). Our results suggest that the VP2 residues involved in VP2-188 
NSP5 VLS formation and in triggering NSP5 hyperphosphorylation are identical.  189 
NSP5 S67D cannot restore VLS formation with VP2 L124A. As previously reported, 190 
NSP5 hyperphosphorylation is triggered by phosphorylation on serine 67 when in the 191 
presence of NSP2 (19) or VP2 (7), due to a mechanism involving casein kinase I alpha 192 
(43, 44). Interestingly, when serine 67 (Fig 4E) is mutated to an aspartic acid, which 193 
mimics a phosphorylated serine, NSP5 gets hyperphosphorylated similarly as upon RV 194 
infection (44). We, therefore, investigated whether NSP5 S67D would allow VLS 195 
formation with the VP2 point mutation L124A. For this, we compared VLS formation of 196 
wt NSP5 and NSP5 S67D with wt VP2 (Fig 4F, upper panel) or VP2 L124A (Fig 4F, 197 
lower panel). As expected, wt NSP5 or NSP5 S67D form VLS with wt VP2 but not with 198 
VP2 L124A. In order to test whether the phosphorylation state of NSP5 S67D was 199 
impaired when co-expressed with VP2 L124A (Fig 4G), we inspected the NSP5 200 
hyperphosphorylation patterns of both wt NSP5 and NSP5 S67D when co-expressed with 201 



































































anticipated, had an increased mobility shift in the presence of wt VP2 but not in the 203 
presence of VP2 L124A, which showed a pattern comparable to that observed when wt 204 
NSP5 is expressed alone. Surprisingly, NSP5 S67D showed a more substantial shift with 205 
wt VP2 (Fig 4G, lane 2), while with VP2 L124A, a single NSP5 band was detected, 206 
similar to that observed when wt NSP5 had expressed alone (Fig 4G, lane 3). Since VP2 207 
triggered NSP5 hyperphosphorylation, we hypothesized that the hypophosphorylation of 208 
NSP5 in the presence of VP2 L124A is impaired because of the lack of interaction 209 
between the two proteins. To address this (Fig 4H), we pulled down cellular extracts co-210 
expressing hexahistidine (H6)-tagged wt NSP5 (H6-NSP5) or NSP5 S67D (H6-211 
NSP5/S67D) with wt VP2 or VP2 L124A. The results showed that independent of the 212 
NSP5 genotype (wt or S67D), VP2 L124 did not bind NSP5 while wt VP2 did. 213 
Collectively, this data suggests that NSP5 and VP2 associate to form VLS independent of 214 
the NSP5 phosphorylation state. 215 
VP2 L124 and I878 are necessary to bind NSP5. To determine if VP2 and NSP5 216 
requirements for VLS formation correlate with their ability to associate, we performed a 217 
pull-down assay by adding an H6 tag at the N-terminus of NSP5 (H6-NSP5) followed by 218 
co-expression with wt VP2 or VP2 L124A, VP2 V865A or VP2 I878A point mutations 219 
(Fig 5A). As expected, wt VP2 associated with NSP5, as evident by the presence of wt 220 
VP2 in the eluted fraction (Figs 5A, lane 3). By contrast, VP2 L124A was not detected in 221 
the elution (Fig 5A, lanes 6), suggesting no association to H6-NSP5. Also, VP2 V865A 222 
got eluted from the pull-down assay (Fig 5A, lane 9). Meanwhile, VP2 I878 weakly 223 
eluted, suggesting no or weak association to NSP5 (Fig 5A, lane 12). Interestingly, when 224 



































































shift in PAGE (Fig 5A, lane 3), which represents the NSP5 hyperphosphorylated fraction. 226 
The H6-NSP5 eluted fraction obtained by co-expression with VP2 L124A showed a 227 
unique band that correlated with the unphosphorylated NSP5 isoform. 228 
NSP5 amino acid residues 180-198 are necessary for the association with VP2. It was 229 
previously described that the NSP5 tail (T), corresponding to residues 180-198, is needed 230 
for its dimerization (9, 12, 44) and to associate with NSP2 (9, 35), NSP6 (12) and VP1 231 
(23). Using a pull-down assay, we tested (Fig 5B and C) the capacity of an H6-tagged, 232 
tail-deleted NSP5 (H6-NSP5∆T) to bind to VP2. The results show that H6-NSP5 can bind 233 
VP2 while H6-NSP5∆T did not. Likewise, H6-NSP5∆1∆3, an NSP5 deletion mutant 234 
known to allow self-dimerization (44), pulled-down VP2 whereas the same NSP5 235 
deletion mutant but without the tail region (H6-NSP5∆1∆3∆T) did not (Fig 5B and D). 236 
Interestingly, H6-NSP5∆1∆3 was neither able to pull down VP2 L124A (Fig 5B and E). 237 
To confirm these results, we constructed an H6-tagged EGFP fused at its C-terminus with 238 
the NSP5 tail (H6-EGFP-T) or region 4 (amino acid residues 134-180; H6-EGFP-4). The 239 
fusion constructs were co-expressed with wt VP2 and pulled-down with nickel resin to 240 
detect an association with VP2. As shown in Fig 5F and E, H6-EGFP-T can bind VP2 241 
while H6-EGFP and H6-EGFP-4 cannot. Collectively, these results indicate that the NSP5 242 
tail is required for the association with VP2. 243 
VP2 and NSP5 are protein-protein interaction partners. The next experiment was 244 
performed to determine whether VP2 and NSP5 proteins can interact directly. For this, 245 
we employed the recently developed tripartite split-GFP association assay (45). As shown 246 



































































VP2 or VP2 point mutations), respectively. The detector fragment GFP1-9OPT is added 248 
separately. When protein interaction occurs (i), GFP10 and GFP11 are tethered and 249 
spontaneously associate with the GFP 1-9 fragment to form a full-length GFP, which 250 
fluoresces green. If the bait and prey do not interact (ii) GFP10 and GFP11 are not 251 
tethered, and the assembly of GFP10, GFP11, and GFP 1-9 does not occur (45); 252 
therefore, no green fluorescence is detected by flow cytometry. As expected, neither 253 
GFP10-NSP5 nor GFP11-VP2 produced green fluorescence when expressed together 254 
with GFP11 or GFP10, respectively (Fig 6B and data not shown). By contrast, co-255 
expression of GFP10-NSP5 with GFP11-VP2 produced green fluorescent cells showing a 256 
direct interaction between wt NSP5 and wt VP2. Consistent with the data of the Fig 5A, 257 
co-expression of GFP10-NSP5 with either GFP11-VP2 L124A or GFP11-VP2 I878A did 258 
not generate green fluorescent cells, thereby confirming their incapacity to interact. By 259 
contrast, GFP10-NSP5, together with GFP11-VP2 V865A, as well as GFP10-(T)NSP5 260 
together with GFP11-VP2, produced green fluorescent cells. This data confirmed that the 261 
NSP5 tail is necessary for the interaction with VP2. Next, we investigated whether VP2 262 
L124A would bind to the wtVP2 and thus perturb its interaction with NSP5. To address 263 
this question (Fig 6C), we expressed the protein-protein interaction (PPI) partner GFP10-264 
NSP5 and GFP11-VP2 together with an increasing amount of GFP11-VP2 L124A. As 265 
anticipated, the PPI partner NSP5-VP2 yielded a high number of green fluorescent cells 266 
that were reduced upon the addition of VP2 L124A in a dose-dependent manner, 267 
suggesting a reduction in the binding between NSP5 and wt VP2. 268 
VP2 L124A hinders the formation of VLS(NSP5+HA-VP2) and VLS (NSP5+NSP2). 269 



































































that increased amounts of VP2 L124A would disrupt VLS(NSP5+HA-VP2). To 271 
investigate this possibility, we co-expressed NSP5 and HA-VP2 to permit the formation 272 
of VLS(NSP5+HA-VP2). As shown in Fig 1B and data not shown, VLS(NSP5+HA-273 
VP2) can be readily detected as yellow-fluorescent cytosolic inclusions upon staining 274 
with anti-NSP5 (red) and anti-HA (green) antibodies. With increasing amounts of wt 275 
VP2, the color of the VLS shifted to red (Fig 7A), reflecting competition between wt VP2 276 
and HA-VP2. With increasing amounts of VP2 L124A, the cytosolic inclusions became 277 
disrupted (Fig 7B). Using the same approach, we then tested whether overexpression of 278 
VP2 L124A hinders VLS(NSP5+NSP2) formation. Co-expression of NSP5 and NSP2 279 
resulted in the formation of VLS(NSP5+NSP2), readily detected as yellow-fluorescent 280 
cytosolic inclusions upon staining with anti-NSP5 (red) and anti-NSP2 (green) 281 
antibodies; VP2 (anti-VP2, green) was not detected (Fig 7C, upper panel). Upon co-282 
expression of NSP5, NSP2, and wt VP2, all three proteins co-localized in the cytosolic 283 
VLS (Fig 8C, middle panel). However, when co-expressing NSP5, NSP2, and VP2 284 
L124A, unstructured VLSs were detected (Fig 7C, lower panel). In support of this result 285 
(data not shown), a drastic reduction (p<0.001) in the number of cells showing 286 
VLS(NSP5+NSP2) is observed in co-expression with VP2 L124A (12.8%) compared to 287 
wt VP2 (38.3%). Additionally, 100% of VLS(NSP5+NSP2) formed with wt VP2 showed 288 
a globular morphology that is in contrast with the reduced number (36%) of globular 289 
structures observed among the VLS (NSP5+NSP2) formed with VP2 L124A (data not 290 
shown). Accordingly, VP2 L124A expression blocked the formation of both 291 



































































VP2 L124A expression affects viroplasm morphology. As VLSs are a simplified 293 
model to study viroplasms, we interrogated whether overexpression of VP2 L124A could 294 
also compromise viroplasms formation. For this purpose, we overexpressed either wt 295 
VP2 or VP2 L124A in BSR-T7 cells (Fig 8A) followed by RV-infection and quantified 296 
cells showing viroplasms under these two conditions. As shown in Fig 8B, the number of 297 
cells with viroplasms was significantly reduced upon co-expression of VP2 L124A 298 
compared to cells expressing wt VP2. Interestingly, most viroplasms in cells expressing 299 
VP2 L124A presented an atypical filamentous (Fig 8C, frames i and ii) or diffuse and 300 
juxtanuclear polarized (Fig 8C, frames iii and iv) morphology. In contrast, viroplasms 301 
formed in the presence of wt VP2-cells showed a characteristic globular morphology (Fig 302 
8C, frames v and vi). Since viroplasms are composed of several host and viral proteins, as 303 
well as ssRNAs and dsRNAs, we investigated if the localization of the viral proteins 304 
diverges in viroplasms of cells expressing VP2 L124A. For this purpose, RV infected 305 
BSR-T7 cells expressing wt VP2, or VP2 L124A, were stained with specific antibodies 306 
detecting viroplasm proteins such as NSP5, VP2, VP6, and NSP3 (Fig 8D and data not 307 
shown). As expected, (Fig 8D, left panel and data not shown), the viroplasms formed in 308 
the presence of wt VP2 expression exhibit delineated globular structures when detected 309 
for the tested proteins. However, in the cells expressing VP2 L124A, the viral protein 310 
components of viroplasms, including NSP2 and VP6, showed a diffuse pattern (Fig 8D, 311 
right panel, and data not shown). For NSP3 and the capsid proteins (VP6, VP7, and VP4, 312 
detected by anti-RV antibody), even amyloid-like structures were observed that 313 
surrounded aberrant viroplasm structures. Collectively, our data indicate that viroplasm 314 



































































VP2 L124A expression precludes transcription and replication. Since VP2 L124A 316 
expression disrupts viroplasm morphology, we inspected if other functions of viroplasms 317 
such as viral transcription and replication are also inhibited. The synthesis of RV (+) 318 
ssRNA, as a template for dsRNA generation, is uniquely dependent on RdRp-VP1 (46). 319 
We assessed RV transcription by treating RV-infected BSR-T7 cells expressing wt VP2 320 
or VP2 L124A at 4 hpi with actinomycin D for 30 min (Fig 9A). Of note, actinomycin D 321 
has been shown to not interfere with the RdRp activity of VP1 (47). Then, the cells were 322 
fed with BrUTP for 1 h, and the incorporation signal was monitored by 323 
immunofluorescence using a fluorescence-labelled anti-BrdU antibody. The viroplasms 324 
were stained with an anti-NSP5 antibody. Cells not treated with BrUTP were used as 325 
control. As expected (46), cells expressing wt VP2 incorporated BrUTP in viroplasms 326 
(Fig 9A, upper row) indicating RV viral transcription, while cells expressing VP2 L124A 327 
did not (Fig 9A, lower row). To confirm our result, we stained RV-infected cells 328 
expressing wt VP2 or VP2 L124A with an anti-dsRNA antibody (clone J2) that can 329 
recognize dsRNA with a size larger than 40 base pairs (48). In non-infected cells (Fig 9B, 330 
-RV), punctuated anti-dsRNA signal was found distributed in the whole cytoplasm. Upon 331 
RV-infection (Fig 9B, +RV), most of the dsRNA signal localized to viroplasms in both 332 
non-transfected and wt VP2 expressing cells. These results are also confirmed by 333 
intensity profiles among the signals of both viroplasms and dsRNA (Fig 9C). Such 334 
pattern, however, is not repeated in VP2 L124A expressing cells, where none or mild 335 
localization of anti-dsRNA signal in viroplasm and no coincidence of these signals in the 336 
intensity profile plot was observed (Fig 9C). Thus, our results suggest that RV RNA 337 




































































  In RV viroplasms several processes take place, including viral transcription, 340 
packaging of the viral pre-genomic RNA into newly synthesized viral cores and RNA 341 
replication, followed by the addition of the second layer of proteins. None of these 342 
processes have been directly demonstrated as a whole in the viroplasms, and all the 343 
current evidence is based on in vitro data, providing models, such as the packaging of the 344 
virus genome (49). The fact that rotavirus encodes only a small number of proteins, 345 
eleven or twelve (NSP6 is present only in certain RV strains (50-53)), supports the 346 
hypothesis that at least some viral proteins have multifunctional roles in the replication 347 
cycle. A clear example is VP2, which is well characterized as the RV core-shell 348 
encapsidating the viral genome (2, 32, 33, 54, 55), acting as co-factor of RdRp VP1 (28, 349 
30, 39), and anchoring VP6 to form DLPs (34, 55). Aside from its structural functions, 350 
VP2 has other roles during the RV life cycle, such as permitting perinuclear motion of 351 
viroplasms (10) or being associated with the RV induced cell cycle arrest (56). Another 352 
exciting aspect is its role as the main building block for viroplasm formation. In this 353 
sense, the co-expression of NSP5 with either NSP2 or VP2 forms VLSs denoting the role 354 
of VP2 in viroplasm formation (7, 10, 41). In the present study, we fully characterized the 355 
interaction between NSP5 and VP2 proteins and the importance of this interaction for 356 
VLS formation. In this context, we identified three amino acids in VP2 of simian RV 357 
strain SA11, L124, V865, and I878 that are highly conserved among cognate proteins of 358 
all RV species present in the NCBI data bank. As observed in the calculated 3D model 359 
for VP2-SA11, V865, and I878 (data not shown) are positioned behind the beta-strand 360 



































































when modified to alanine, can directly abrogate VP2 dimerization and VLS formation, 362 
indicating that VP2 dimerization is a requirement for VLS formation, in concomitant 363 
association with NSP5. A particular example corresponds to VP2 point mutation V865A 364 
and I878, which associate with NSP5, as demonstrated by binding assays, but support 365 
neither VLS formation nor NSP5 hyperphosphorylation. Moreover, VP2 L124A impairs 366 
VLS formation and NSP5 hyperphosphorylation in either NSP5 from RV strains OSU or 367 
SA11. This outcome was not surprising since both strains have a 95% identity (Fig 3C), 368 
where the NSP5 tails (region 180-198) and CKI non-canonical phosphorylation site for 369 
S67D are identically conserved. 370 
  Interestingly, the residue L124 faces towards the VP2 inner central domains (data 371 
not shown), and its modification to alanine affects VLS formation, the direct association 372 
with NSP5, and the NSP5 phosphorylation state. Therefore, it suggests that the VP2-373 
NSP5 interaction interface may impede core assembly to favor viroplasm formation and 374 
allow the packaging of genome segments. We show that NSP5 can associate with VP2 375 
through its tail region (residues 180-198). This finding is not surprising since the role of 376 
NSP5 tail has previously been described to play a role in association with other viral 377 
proteins, including NSP2 (9, 35), NSP6 (12), and VP1 (23) and even as a self-378 
oligomerization domain (12, 44). 379 
Collectively, our data show that NSP5-VP2 interaction and VLS formation are 380 
immediate prior steps to the NSP5 hyperphosphorylation. In support of this viewpoint, 381 
we provide data showing that: i) a hyperphosphorylated NSP5 (NSP5 S67D) is not 382 



































































VP2 L124A does not hyperphosphorylate wt NSP5, and iv) NSP5/S67A forms VLS with 384 
wt VP2 (7). Our conclusion then provides additional insights into the molecular 385 
mechanism previously proposed (44, 58) for the formation of viroplasms and subsequent 386 
NSP5 hyperphosphorylation. This mechanistic interpretation is consistent with previous 387 
observations that viroplasm formation requires a phosphorylation cascade triggered by 388 
NSP2, which depends on CK1-alpha (43, 44, 59). Also, it is consistent with the fact that 389 
NSP5 phosphorylation on S67 by CK1-alpha is a step after the interaction with VP2 ((7) 390 
and this study) and NSP2 (19, 44, 58). The phosphorylation of other serines and 391 
threonines of NSP5 by host cell kinases (8, 43, 60) will follow in agreement with a model 392 
previously described (44, 58). Our data also suggest that the NSP5-VP2 interaction relies 393 
on conserved L124 of VP2. 394 
As described above, NSP2 and VP2 can both trigger NSP5 hyperphosphorylation. We 395 
provide evidence also that VP2-NSP5 interaction, similar to NSP2-NSP5 interaction, 396 
provides a scaffold for viroplasms formation. Impairment of the NSP5-VP2 interaction, 397 
for example by VP2 L124A, abolishes the formation of VLS and viroplasms. This 398 
observation is consistent with the previous model for viroplasm formation (44, 58, 59), 399 
whereas NSP5 hyperphosphorylation is an initial step followed by the cytosolic inclusion 400 
formation in association with both NSP2 (58) and VP2 (this study). 401 
A dominant-negative refers to a mutation in a protein that adversely affects the wild-402 
type phenotype, for example, by disrupting a functional domain but retaining its 403 
dimerization property. Therefore, the dominant-negative protein can dimerize with the 404 



































































protein (61). We provide strong evidence that VP2 L124 works as a dominant-negative 406 
protein for the formation of both VLSs and viroplasms. In this sense, we have shown that 407 
i) VP2 L124 disrupts both VLS(NSP5+VP2) and VLS(NSP5+NSP2), ii) NSP5-VP2 408 
interaction, in the split tripartite EGFP assay, is reduced in a dose-dependent manner with 409 
VP2 L124 and iii) NSP5 and VP2 L124A neither form VLS nor bind to each other. Thus, 410 
we conclude that VP2 L124A necessarily dimerizes with wt VP2 displacing NSP5 - wt 411 
VP2 interaction. It is well described that NSP2 binds VP2 at several amino acid regions 412 
(residues 34-86, 514-518, 664-674, and 836-845) (35). Hence, VP2 L124A also acts as 413 
dominant-negative over NSP2, because VP2 L124A preserves NSP2 binding sites but did 414 
not allow VLS formation. Moreover, the NSP2-VP2 interaction seems stronger than the 415 
NSP5-VP2 interaction. We provide evidence for the idea that VP2 L124A can disrupt 416 
viroplasms by showing that the expression of VP2 L124A interferes with RV replication 417 
by damaging viroplasms. Specifically, viroplasms upon VP2 L124A expression form i) 418 
aberrant inclusions, and ii) delocalize viroplasmic viral proteins in diffuse cytosolic 419 
patterns or amyloid-like structures. Moreover, iii) these aberrant viroplasms are decreased 420 
in viral transcription (+ssRNA synthesis) and dsRNA synthesis. Hence, VP2 L124A 421 
works as a bona fide dominant-negative factor for the assembly and formation of 422 
viroplasms. Accordingly, a point mutation on VP2 L124 to alanine on RV and possible 423 
rescue by reverse genetic technique (62), would undoubtedly provide new insights into 424 
the regulation of the RV life cycle. However, several attempts to rescue a recombinant 425 
RV harboring VP2 L124A were performed without success, in contrast to the control 426 
recombinant RV that retains wt VP2 (data not shown), reinforcing the relevance of this 427 



































































We consider that this study could lay the foundations for the designing of inhibitors 429 
that specifically bind at the interaction site between NSP5 and VP2.  430 
Materials and Methods 431 
Cells and viruses. MA104 cells (embryonic rhesus monkey kidney, ATCC
®
CRL-2378) 432 
and Hek293T cells (human embryonic kidney, ATCC
®
CRL-573) were cultured in 433 
DMEM (Dulbecco’s modified Eagle’s media (DMEM, Gibco®BRL) supplemented with 434 
10% fetal calf serum (FCS) (AMIMED, BioConcept, Switzerland) and penicillin (100 435 
U/ml)-streptomycin (100 µg/ml) (Gibco, Life Technologies). BSR-T7 cells (Baby 436 
hamster kidney, CVCL-RW96), which express T7 DNA directed RNA polymerase were 437 
cultured in DMEM supplemented with 10 % FCS, 1 mg/ml Geneticin® (G418, Thermo 438 
Fisher Scientific) and penicillin (100 U/ml) –streptomycin (100 µg/ml). The T7 RNA 439 
polymerase recombinant vaccinia virus (strain vvT7.3) was amplified as previously 440 
described (63).  441 
 Rotavirus porcine OSU strain (G5;P[9]) was propagated in MA104 cells, as 442 
described previously (64, 65). Virus titer was determined as described previously by 443 
Eichwald et al., (10) and expressed as viroplasm-forming units (VFU) per milliliter. 444 
Antibodies. Guinea pig anti-NSP5, guinea pig anti-NSP2, guinea pig anti-VP2, and 445 
Mouse scFV anti-NSP5 clone 1F2 were described previously (8, 19, 23, 66). Guinea pig 446 
anti-VP6 was described (10, 67). Mouse monoclonal anti-VP6 (clone 2F) was a gift from 447 
Dr. N. Mattion (CEVAN, Buenos Aires, Argentina). Rabbit anti-NSP3 was kindly 448 



































































(clone3E8) was kindly provided by Dr. Harry Greenberg (Stanford University, CA, 450 
USA). Mouse mAb anti-HA (clone HA-7) and mouse monoclonal anti-GAPDH (clone 451 
GAPDH-71.1) were obtained from Sigma Aldrich.  Mouse mAb anti-dsRNA (clone J2) 452 
was purchased from SCICONS J2, English&Scientific consulting, Hungary. Goat anti-453 
mouse immunoglobulin G (IgG) (H+L) conjugated to Alexa 594 and goat anti-guinea pig 454 
IgG conjugated to Alexa 488 were obtained from Molecular Probes, Invitrogen, USA. 455 
Goat polyclonal anti-mouse IgG (Fab’)-peroxidase was purchased from Sigma Aldrich. 456 
Rabbit polyclonal anti-guinea pig IgG-peroxidase was purchased from Dako Cytomation, 457 
Denmark. 458 
Plasmid constructions. The plasmids pcDNA-NSP5 porcine strain OSU (G5;P[9]), 459 
pcDNA-NSP5 simian strain SA11-4F (G3;P6[1]), pcDNA-NSP2 simian strain SA11-4F 460 
(G3;P6[1]), and pcDNA-VP2 simian strain SA11-4F (G3;P6[1]) were previously 461 
described (11, 19, 21, 23). The plasmids pCI-HA-VP2 full-length, pCI-HA-VP2∆N81, 462 
pCI-HA-VP2∆N103, pCI-HA-VP2∆N135, pCI-HA-VP2∆N159, pCI-HA-VP2∆N181, 463 
pCI-HA-VP2∆N203, pCI-HA-VP2∆N316, pCI-HA-VP2∆N588, pCI-HA-VP2∆N720, 464 
pCI-HA-VP2∆C81, pCI-HA-VP2∆C203, pCI-HA-VP2∆C316, pCI-HA-VP2∆C588, pCI-465 
HA-VP2∆C721, pCI-HA-VP2∆C755, pCI-HA-VP2∆C840, pCI-HA-VP2(82-203), pCI-466 
HA-VP2(204-316), pCI-HA-VP2(317-588) and pCI-HA-VP2(589-720) were obtained by 467 
PCR amplification of pcDNA-VP2 (23) using specific primers to insert flanking 468 
XhoI/HA-tag and EcoRI sites, followed by ligation into those sites in pCI-Neo (Promega). 469 
Similarly, pCI-VP2∆N81, pCI-VP2∆N203, pCI-VP2∆N316, pCI-VP2∆N588, pCI-470 



































































VP2∆C720 were obtained by PCR amplification of pcDNA-VP2 using specific primers 472 
to insert XhoI and EcoRI sites, followed by ligation into those sites in pCI-Neo. 473 
The constructs pCI-H6-NSP5, pCI-H6-NSP5 S67D, pCI-H6-EGFP, pCI-H6-EGFP-T, 474 
and pCI-H6-EGFP-dom4 were obtained from PCR amplification of pcDNA-NSP5 (11), 475 
pcDNA-NSP5 S67D (44), pEGFP-N1 (Clontech), p(1-EGFP-T) (9) and p(EGFP-4) (9) 476 
using specific primers to insert XhoI/hexahistidine tag and NotI sites, following by 477 
ligation on those sites in pCI-Neo (Promega). The construct pcDNA-H6-∆1∆3 was 478 
previously described (8). The constructs pCI-H6-NSP5∆T and pCI-H6-∆1∆3∆T were 479 
obtained by PCR amplification of pcDNA-H6-NSP5and pcDNA-H6-∆1∆3 using specific 480 
primers for the insertion of a XhoI restriction site at the 5’-end and the reverse 481 
oligonucleotide primer 5’-gatcgcggccgcttagaagcaccttttcttatattt-3’ for the deletion of NSP5 482 
tail and insertion of Stop codon/NotI site at the 3’-end. The PCR fragment was ligated 483 
between XhoI/NotI sites in pCI-Neo (Promega). The plasmids pCI-mCherry and 484 
pcDNA3.1tn(+)-GFP1-9OPT were previously described (45, 68). The construct p10L-485 
NSP5 was obtained by PCR amplification of pcDNA-NSP5 using specific primers to 486 
insert PacI and XhoI sites, following by ligation in-frame in pcDNA3.1tn(+)GFP10+long 487 
linker (45). The construct p10L-NSP5 (T) was obtained by annealing of the 488 
oligonucleotides 5’-taacattgcactaagaatgaggatgaagcaagtcgcaatgcaattgatcgaagatttgtaac-3’ 489 
and 5’-tcgagttacaaatcttcgatcaattgcattgcgacttgcttcatcctcattcttagtgcaatgttaat-3’, followed by 490 
ligation into PacI and XhoI sites of pcDNA3.1tn(+)-GFP10+long linker (45). The 491 
construct p11L-VP2 was obtained by PCR amplification of pcDNA-VP2 using specific 492 




































































pCAG-D1R (Addgene plasmid #89160) and pCAG-D12L (Addgene plasmid # 495 
89161) were a gift from Takeshi Kobayashi (62). 496 
Version of constructs pCDNA-VP2, pCI-HA-VP2(∆N103) and p11L-VP2 harboring 497 
the VP2 point mutations I106A, D112A, L124A, R125A, I127A, M843A, F850A, 498 
L856A, V860A, F865A, F873A, F878A, V865A or I878A were built by insertion of 499 
point mutations using the QuickChange Site-Directed Mutagenesis kit and protocol 500 
(Agilent). All the oligonucleotides were obtained from Microsynth AG, Switzerland, and 501 
are available upon request. 502 
Immunofluorescence. For VLS detection, 1 x 10
5
 MA104 cells per well were seeded in 503 
24 well multiwell plates over coverslip. Cells infected with vvT7.3 (3 PFU/cell) were 504 
transfected for 15 hpt in an empirically determined ratio 2:1 of NSP5 and VP2, using 505 
Lipofectamine® 2000 (Thermo Fisher Scientific) according to the manufacturer’s 506 
instructions. For viroplasms detection, transfected BSR-T7 cells were infected for 5 h at 507 
an MOI of 75 VFU/cell. At the indicated time post-infection, cells were fixed in 2% 508 
paraformaldehyde in PBS for 10 min at room temperature and processed as described by 509 
Eichwald et al., 2012 (10). When indicated, images were acquired using a fluorescence 510 
microscope (Leica, DMI6000B) or a CLSM (Leica, DM550Q). Data were analyzed with 511 
Leica Application Suite (Mannheim, Germany) and Image J (version: 2.0.0-RC-69/1.52i; 512 
http://imagej.net/Contributors). Images were prepared for publication using PowerPoint 513 
(Microsoft) and Adobe Photoshop® Softwares. The intensity profile plots were obtained 514 



































































Pull-down assay. MA104 cells were infected with vvT7.3 (MOI, 3 PFU/cell), followed 516 
by transfection at ratio 1:1 of two DNA plasmids using Lipofectamine
®
 2000 (Thermo 517 
Fisher Scientific) according to manufacturer instructions. At 16 hpt, cells were processed 518 
as described previously (69) 519 
Hyperphosphorylation assay. The assay was performed as described by Eichwald et al., 520 
2004 (44). Briefly, 2x10
5
 cells in 12 wells multi-well plate were infected with T7 RNA 521 
polymerase recombinant vaccinia virus (vvT7.3) (63) (MOI, 3 PFU/cell) followed by 522 
transfection with 2 µg of total plasmid DNA (1 µg of the substrate and 1µg activator) and 523 
3 µl Lipofectamine
®
 2000 Transfection reagent (ThermoFisher Scientific). At 16 hpt, 524 
cells were lysed in 30 µl of TNN lysis buffer (100 mM Tris-HCl pH 8.0, 250 mM NaCl, 525 
0.5% Nonidet P-40 and cOmplete protease inhibitor cocktail (Roche, Switzerland)) for 10 526 
min at 4˚C. Samples were harvested and centrifuged at 17'000 x g for 7 min at 4˚C. The 527 
supernatant was analyzed by immunoblotting, as described previously (10). 528 
Lambda-phosphatase assay. Cellular extracts were treated with lambda phosphatase, as 529 
described by Eichwald et al., 2004 (44). For analysis, samples were loaded in SDS-530 
polyacrylamide and analyzed by immunoblotting for the detection of NSP5 (10). 531 
Protein-protein interaction tripartite split-GFP assay. The assay was performed as 532 
previously described by Cabantous et al., 2013 (45). Briefly, 5x10
4
 per well of Hek293T 533 
cells are seeded in 48 multi-well plates. Cells were co-transfected by mixing 20 ng pCI-534 
mCherry, 60 ng pcDNA3.1tn(+) GFP1-9 OPT, 60 ng p10L-NSP5 and 60 ng p11L-VP2 535 
using with 1µl Lipofectamine
®





































































(Thermo Fisher Scientific) followed by 20 min incubation at room temperature. The 537 
transfection mixture was added to the cells held under 160 µl of DMEM supplemented 538 
with 10% FCS. At 24 hpt, cells were released with trypsin-EDTA, harvested in cDMEM, 539 
and centrifuged at low speed for 2 min. Cellular pellets were resuspended in FC buffer (5 540 
mM EDTA pH 8.0, 2% FCS in PBS), filtered in cell strained snap-cap tube (BD 541 
Falcon
TM
) and immediately acquired in a Gallios
TM
 Flow Cytometer (Beckman Coulter, 542 
Inc). In total, 10,000 events were acquired exciting with 488 nm and 561 nm lasers 543 
followed by recording with default filters of 525/50 nm (GFP, green) and 620/30 nm 544 
(mCherry, red), respectively. Data were analyzed normalizing the number of green cells 545 
to 10'000 events on the positive red population using a Kaluza® Flow Analysis Software. 546 
The statistical analysis and plot were performed using Microsoft® Excel® for MAC 2011 547 
Version 14.7.3. and also, Prism 8 (GraphPad Software, Inc.). 548 
Dominant-negative assay for viroplasm formation. BSR-T7 cells (2x10
5
) seeded in 24-549 
well plates over coverslip were transfected with 1µg pcDNA-VP2 or pcDNA-VP2 550 
L124A, 0.1µg pCAG-D1R and 0.1µg pCAG-D12L using Lipofectamine
®
 2000 according 551 
to manufacturer’s instructions. At 24 hpt, cells were infected with porcine rotavirus strain 552 
OSU at indicated MOI. The virus was adsorbed for 1 h at 4˚C, followed by incubation at 553 
37˚C. At 5 hpi, cells were fixed 2% paraformaldehyde in PBS for 10 min at room 554 
temperature and processed for immunofluorescence as described by Eichwald et al., 2012 555 
(10). The number of cells containing viroplasms and the total number of cells per field 556 
was counted for at least 40 fields using a fluorescence microscope. The percentage of 557 
viroplasms, plot, and statistical analysis were performed with Microsoft® Excel® 2011 558 



































































Detection of RNA synthesis in viroplasm. BSR-T7 cells (2x10
5
), seeded over coverslip 560 
in 24-well plate, were transfected for expression of wt VP2 and VP2 L124A, as described 561 
above. At 24 hpt, cells were infected with porcine RV strain OSU at MOI of 75 VFU/cell. 562 
The virus was adsorbed for 1 h at 4˚C, followed by incubation at 37˚C. BrUTP (5-563 
Bromouridine 5’-triphosphate sodium salt, Sigma-Aldrich) incorporation was performed 564 
as described previously by Silvestri et al., 2004 (46) with some modifications. Briefly, 565 
cells were pretreated for 30 min with 10 µM actinomycin D (GeneTex) in 500 µl serum-566 
free medium starting at 4 hpi. At 4.5 hpi, cells were transfected with a mixture containing 567 
1 mM BrUTP, 10 µM actinomycin D and 20 µl of Lipofectamine
®
 2000 transfection 568 
reagent (ThermoFisher Scientific) in 500 µl Opti-MEM reduced serum medium 569 
(ThermoFisher Scientific) and incubated for 1 h at 37˚C and 5% CO2.  The cells were 570 
immediately fixed in 2% paraformaldehyde in PBS for 10 min at room temperature and 571 
processed for immunofluorescence by staining with Alexa Fluor
® 
488 anti-BrdU clone 572 
3D4 (diluted 1:50, BioLegend
®
) and guinea pig anti-NSP5 (1:200) followed by a 573 
secondary antibody conjugated to rhodamine isothiocyanate (RITC). Images were 574 
subsequently acquired at CLSM (Leica, DM550Q) and images analyzed using Imaris File 575 
Converter 9.0.0 and Image J (version: 2.0.0-RC-69/1.52P; http://imagej.net/Contributors). 576 
Images were prepared for publication using PowerPoint (Microsoft) and Adobe 577 
Photoshop
®
 Softwares. 578 
Sequence Alignments. To identify highly conserved amino acids among cogent proteins 579 
of all RV species, an alignment for two VP2 (simian strain SA11) regions (aa 103-135 580 
and aa 840-880) of all VP2 available in the protein depository of the NCBI was 581 



































































software (71). The obtained alignments were further processed using Jalview software 583 
(72). The following selected sequences from rotavirus species (A-H) are represented in 584 
the alignments (species, strain, host and GenBank version accession number listed for 585 
each): RVA_K9 (ca)(EU7089240); RVA_SA11_lab (si)(MK184911); RVA_SA11-H96 586 
(si) (NC_011506); RVA_Vanderbilt_VU08-09-24 (hu) (JF491072); 587 
RVA_Vanderbilt_VU08-09-25 (hu)(JF491082); RVA_Vanderbilt_VU05-06-15 588 
(hu)(JF490598); RVA_Vanderbilt_VU06-07-29 (hu)(JF490852); RVA_Wa 589 
(hu)(X14942); RVA_PO-13(av)(AB009630); RVA_EB(mu)(HQ540508); 590 
RVA_02V0002G3 (av)(FJ169854); RVA_Cowden (po)(M74217); RVA_OSU 591 
(po)(ADE44253); RVB_WH-1 (hu)(AY539859); RVB_ADRV (hu)(M91433); 592 
RVB_Bang373(hu)(NC_021545); RVB_IDIRg2 (ra)(U00673); RVB_RUBV226 593 
(bo)(GQ358717); RVC_Bristol (hu)(NC_007546); RVD_05V0049/DEU/2003 (av) 594 
(YP_003896047); RVF_03V0568/DEU/2003 (av)(NC_021626); RVG_HK18 595 
(av)(KC876011); RVG_03V0567/DEU/2003 (av)(NC_021580); 596 
RVH_MRC_DPRU1575 (po) (KT962028); and RVH_J19 (hu) (DQ113898). The 597 
indicated hosts are: ca, canine; si, simian; hu, human; av, avian; mu, murine; po, porcine; 598 
ra, rabbit; bo, bovine. 599 
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Figure Legends 827 
Figure 1. VP2 amino acid regions 103-134 and 840-880 are necessary for VLS 828 
formation. (A) Schematic representation of VP2 deletion mutants fused to an HA-tag at 829 
the N-terminus (not to scale). The dashed lines correspond to deleted regions. Positive (+) 830 
or negative (-) VLS phenotype is indicated at the right. N-terminal (NTD), central, apical, 831 
and dimerization (dim) VP2 tertiary domains are indicated. (B) Representative 832 
photomicrographs of MA104 cells expressing the indicated N- and C-terminal of HA-833 
VP2 deletion mutants alone (-NSP5 panel) or together with NSP5 (+ NSP5 panel). At 16 834 
hpt, cells were fixed and immunostained for detection of HA-VP2 deletion mutant (anti-835 
HA, red) and NSP5 (anti-NSP5, green). A merged image is shown in the right column. 836 
Nuclei were stained with DAPI (blue). White arrows point to VLSs. Scale bar is 10 µm. 837 
Figure 2. VP2 residues L124, V865, and I878 are required for VLS formation. 838 
Alignment of rotavirus VP2 (strain SA11) amino acid region 103-135 (A) and region 839 
840-880 (B). The VP2 amino acid sequences of several representative virus strains are 840 
shown. GenBank accession numbers are listed in Materials and Methods. Members of 841 



































































blue. Amino acid residues mutated to alanine are indicated on the top. (-) indicates 843 
deletion. (B) Immunofluorescence of MA104 cells expressing wt VP2 or point mutations 844 
alone (-NSP5 column) or together with NSP5 (+ NSP5 panel). At 16 hpt, cells were 845 
fixed, and VLSs were detected by immunostaining of HA-VP2 (anti-HA, red) or VP2 846 
(anti-VP2, green) with NSP5 (anti-NSP5, green or red). A merged image is shown in the 847 
right column. Nuclei were stained with DAPI (blue). Scale bar is 10 µm.  848 
Figure 3. VLS formation and triggering of NSP5 hyperphosphorylation from 849 
cognate and non-cognate strains are sensitive to VP2 L124A. (A) 850 
Immunofluorescence of MA104 cells for detection of VLS composed of NSP5 from 851 
simian strain SA11 (top panel) or NSP5 from porcine strain OSU (bottom panel) in co-852 
expression with VP2 from simian strain SA11 wt or L124A.  At 16 hpt, cells were fixed 853 
and immunostained for detection of NSP5 (anti-NSP5, green) and VP2 (anti-VP2, red). A 854 
merged image is at the right column of each panel. Nuclei were stained with DAPI (blue). 855 
Scale bar is 10 µm. (B) Immunoblotting of lysates from MA104 cells co-expressing 856 
NSP5 OSU (lanes 1-3) or NSP5-SA11 (lanes 4-6) with VP2-SA11 wt (lanes 2 and 5) or 857 
L124A (lanes 4 and 6). The membranes were incubated with specific antibodies for the 858 
detection of NSP5. Alpha-tubulin was used as a loading control. The red brackets indicate 859 
NSP5 hyperphosphorylation. (C) Sequence alignment of NSP5 from simian strain SA11 860 
and porcine strain OSU. The identity between the two proteins corresponds to 94.95%. 861 
Non-canonical casein kinase I alpha region and oligomerization tail are labeled in blue 862 
and red, respectively. 863 
Figure 4. VP2 residues L124, V865, and I878 are necessary to trigger NSP5 864 



































































(lanes 3-7) (B) deletion mutants with NSP5. NSP5 alone (lane 1) or in co-expression with 866 
wt VP2 (fl; lane 2) is shown. NSP5 in cellular extracts was detected by immunoblot. 867 
Alpha-tubulin was used as a loading control. (C) Immunoblotting of total cellular lysates 868 
expressing NSP5 alone (lane 1) or in co-expression with VP2 wt (lane 2) or point 869 
mutations (lanes 3 to 5). NSP5 hyperphosphorylation was detected with anti-NSP5, and 870 
VP2 was detected with anti-VP2. Alpha-tubulin was used as a loading control. (D) λ-871 
Phosphatase treatment of NSP5 co-expressed with empty vector (-), wt VP2, or VP2 872 
L124A. NSP5 is visualized by immunoblotting. Untreated (-) and treated (+) samples are 873 
indicated. Red brackets indicate the NSP5 mobility shift. The red dots show the NSP5 874 
unphosphorylated isoform. (E) Schematic representation of point mutations in wt NSP5 875 
and NSP5 S67D. S to D modification is indicated in red (44). (F) Immunofluorescence of 876 
MA104 cells for detection of VLSs formed with wt or mutant NSP5 with wt VP2 (upper 877 
panel) or VP2 L124A (lower panel). At 16 hpt, cells were fixed and immunostained for 878 
detection of VLS with anti-NSP5 (green) and anti-VP2 (red). Nuclei were stained with 879 
DAPI (blue). Scale bar is 10 µm. (G) Immunoblotting of total cellular lysates expressing 880 
wt NSP5 (lanes 1-3) or NSP5 S67D (lanes 4-6) with wt VP2 or VP2 L124A. When 881 
indicated, the membranes were incubated with anti-VP2 or anti-NSP5. The brackets 882 
indicate NSP5 hyperphosphorylation smear. (H) Pull-down assay of cell extracts co-883 
expressing H6-NSP5 (lanes 1-2 and 5-6) or H6-NSP5 S67D (lanes 3-4 and 7-8) with wt 884 
VP2 (lanes 1, 3, 5 and 7) or VP2 L124A (lanes 2, 4, 6 and 8). Samples were detected by 885 
immunoblot using anti-NSP5 and anti-VP2 antibodies. Input (lanes 1-4) and elution 886 



































































Figure 5. NSP5 tail and VP2 residues L124 and I878 are required for their 888 
association. (A) Immunoblotting of nickel resin pulled down cellular extracts co-889 
expressing histidine-tagged NSP5 (H6-NSP5) with wt VP2 or harboring the indicated 890 
point mutation (ce, cellular extract input; ft, flow-through and el, column eluate). (B) 891 
Schematic representation of Histidine tagged (H6)-NSP5 deletion mutants used in (C, D, 892 
and E). Amino acid residues delimiting the NSP5 regions are labeled at the top. Not to 893 
scale. (C) Immunoblotting of pulled-down lysates from cells co-expressing H6-NSP5 894 
(lanes 1-3) or H6-NSP5∆T (lanes 4-6) with wt VP2. (D) Immunoblotting of pulled-down 895 
lysates from cells co-expressing wt VP2 with H6-∆1∆3 (lanes 1-3) or H6-∆1∆3∆T (lanes 896 
4-6). (E) Immunoblotting of pulled-down lysates from cells co-expressing VP2 L124A 897 
(lanes 1-3) or wt VP2 (lanes 4-6) with H6-∆1∆3. When indicated the membranes were 898 
incubated with anti-VP2 or anti-NSP5 antibodies. (F) Schematic representation of H6-899 
EGFP fused to NSP5 regions used in assay from E. Not to scale. (E) Plot showing the wt 900 
VP2 binding to H6-EGFP fused to NSP5 C-terminus regions. Data are represented as 901 
mean ± SD of four independent experiments. Student’s t-test (*), p<0.05. 902 
Figure 6. NSP5 and VP2 interact directly. (A) Schematic representation of NSP5-VP2 903 
interaction sensor base in the tripartite split-GFP association. GFP beta strands 10 and 11 904 
are fused to bait, NSP5 or T-NSP5, and prey, wt VP2 or point mutations. The detector 905 
fragment, GFP 1-9, is added separately. When protein interaction occurs (i) GFP10 and 906 
GFP11 are tethered and spontaneously associate with the GFP 1-9 fragment to form a 907 
full-length GFP, which fluoresces in green. If the bait and prey do not interact (ii), GFP10 908 
and GFP11 are not tethered, and entropy is too high to allow complementation with GFP 909 



































































plot is showing the normalized number of green fluorescent cells for the indicated bait-911 
prey pairs. The samples showing a single partner were expressed together with GFP10 or 912 
GFP11. (C) Competition assay plot for NSP5 binding between wt VP2 and VP2 L124A. 913 
In (B-C), data shows the mean ± SEM of six independent experiments. Two-tailed, non-914 
parametric Mann-Whitney test; (***) p<0.001 and (*) p<0.05 compared to NSP5-VP2 915 
green fluorescence. 916 
Figure 7. VP2 L124A disrupts VLS formation. Immunofluorescence of VLS 917 
formation, MA104 cells were expressing NSP5 with HA-VP2 plus increasing amounts 918 
(0.25, 0.5 and 1 µg) of either wt VP2 (A) or VP2 L124A (B). At 16 hpt, cells were fixed 919 
and immunostained for VLS by detecting NSP5 (anti-NSP5, red) and HA-VP2 (anti-HA, 920 
green). Nuclei were stained with DAPI (blue). White arrowheads denote impaired VLS. 921 
Scale bar is 10 µm. (C) Immunofluorescence of VLS(NSP5+NSP2) alone (upper panel), 922 
with wt VP2 (middle panel) or with VP2 L124A (lower panel). At 16 hpt, MA104 cells 923 
were fixed and immunostained for the VLS with anti-NSP5 (red) and anti-NSP2 or anti-924 
VP2 (green). Nuclei were stained with DAPI (blue). A merged image is shown at the 925 
right of each panel. The white arrowheads point to misshaped VLS. Scale bar is 10 µm. 926 
Figure 8. Viroplasms are damaged by VP2 L124A expression. (A) Immunoblotting of 927 
lysates from BSR-T7 cells expressing wt VP2 (lane 2) and VP2 L124A (lane 3) at 48 hpt. 928 
OSU virus particles were used as a positive control (lane 1). (B) Plot of the percentage of 929 
cells showing viroplasms when expressing either wt VP2 or VP2 L124A. A cell was 930 
considered as viroplasm positive when detecting anti-NSP5 cytosolic inclusions. Data are 931 



































































Student’s t-test, (***) p<0.001, n>1500 cells per experimental point. (C) Representative 933 
immunofluorescence images comparing viroplasm morphologies (5 hpi) (anti-NSP5, 934 
green) of cells expressing VP2 L124A (upper panel, frames i, ii, iii and iv) or wt VP2 935 
(lower panel, frames v and vi). Nuclei were stained with DAPI (blue). Scale bar is 10 µm. 936 
(D) Confocal immunofluorescence of RV proteins of cells expressing wt VP2 (left panel) 937 
or VP2 L124A (right panel). At 24 hpt, BSR-T7 cells were RV-infected (MOI, 75 938 
VFU/cell). At 5 hpi, cells were fixed and immunostained for the detection of NSP5 (anti-939 
NSP5, green or red), VP2 (anti-VP2, green), NSP2 (anti-NSP2, green), VP6 (anti-VP6, 940 
red) and NSP3 (anti-NSP3, red) and VP6, VP7 and VP4 (anti-RV, green). Nuclei were 941 
stained with DAPI (blue). Scale bar is 5 µm. 942 
Figure 9. VP2 L124A expression decreases viral transcription and replication of 943 
viroplasms. (A) At 24 hpt for expression of wt VP2 (upper row) and VP2 L124A (lower 944 
row), BSR-T7 cells were RV-infected (MOI, 75 VFU/cell). At 4 hpi, cells were treated 945 
with 10 µM actinomycin D for 30 min and then transfected for 1h with 1mM BrUTP 946 
(+BrUTP) or not (-BrUTP) before fixation. Cells were immunostained for BrUTP 947 
incorporation (anti-BrdU, green) and viroplasms detection (anti-NSP5, red). Nuclei were 948 
stained with DAPI (blue). Scale bar is 5 µm. (B) Confocal immunofluorescence of BSR-949 
T7 cells alone, expressing wt VP2 or VP2 L124A followed at 24 hpt by RV-infection 950 
(MOI, 150 VFU/cell). At 5 hpi, cells were fixed and immunostained for detection of 951 
dsRNA (anti-dsRNA, red) and viroplasms (anti-NSP5, green). Nuclei were stained with 952 
DAPI (blue). N.T., non-transfected cells. Scale bar is 5 µm. (C) Intensity profile plot of 953 
dsRNA (red line) and viroplasms (green line) of the indicated linear region of interest of 954 
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